Ditto Bio discovers drugs for autoimmune diseases by utilizing proteins from parasites, which have evolved to modulate the immune system. Their AI platform identifies these proteins for potential therapeutic applications in treating autoimmune conditions. The company focuses on addressing diseases where the immune system is overactive, such as rheumatoid arthritis and multiple sclerosis.
Cofounder at Ditto Bio (YC W26)
Cofounder at Ditto Bio (YC W26)
Ditto Bio specializes in drug discovery for autoimmune diseases by utilizing proteins derived from parasites. Their main product is an AI platform that identifies these proteins, which have evolved to modulate the immune system. This innovative approach targets conditions characterized by an overactive immune response, such as rheumatoid arthritis and multiple sclerosis.
Key features of Ditto Bio's offerings include:
The benefits of Ditto Bio's offerings include:
Overall, Ditto Bio's focus on leveraging advanced technology and unique biological insights positions it as a promising player in the biopharmaceutical industry.